Browse wiki

Jump to: navigation, search
Dambrova 2018 MiP2018
Has abstract [[Image:MITOEAGLE-logo.jpg|left|100px|link
[[Image:MITOEAGLE-logo.jpg|left|100px|link=|COST Action MitoEAGLE]] L-Carnitine was discovered more than hundred years ago by the Latvian biochemist R. Krimberg [1], but it took more than half a century until its role in long-chain fatty acid oxidation by mitochondria was described. In the 1970-80s, the cases of inborn errors in carnitine metabolism were reported and details of the enzymes and transporters of the carnitine system delineated at the genetic level. Nowadays L-carnitine is a very popular food supplement due to its safety profile and suggested effects on energy metabolism pathways [2]. L-carnitine is frequently used in cocktails of food supplements that are believed to increase fatty acid metabolism, eliminate body fat and increase fitness. However, the scientific evidence supporting its efficacy is inconclusive and the body weight-reducing effect of L-carnitine supplementation has not been proven clinically. In addition, L-carnitine is not considered as a doping agent, but it has been shown to positively impact the recovery process after exercise. To drive the processes of fatty acid metabolism, excessive concentrations of L-carnitine should reach the cellular mitochondria, but its bioavailability during normal homeostasis is quite low. The intake of high doses of L-carnitine impacts body levels of L-carnitine metabolites, long-chain acylcarnitines and trimethylamine-N-oxide. The increase in the tissue and plasma pools of long-chain acylcarnitines has been linked to the disturbed energy metabolism and development of insulin resistance, as well as increased ischemia-reperfusion damage [3]. Elevated trimethylamine-N-oxide levels impair pyruvate and fatty acid oxidation in cardiac mitochondria and predict an increased risk of cardiometabolic diseases and an increased incidence of major adverse cardiac events [4]. More studies are needed to evaluate the hypothesis of long-chain acylcarnitines and trimethylamine-N-oxide as novel diagnostic markers and to use L-carnitine-related pathway regulation to treat cardiovascular diseases and diabetes.
reat cardiovascular diseases and diabetes.  +
Has editor [[Plangger M]]  + , [[Kandolf G]]  +
Has title [[Image:MiPsocietyLOGO.JPG|left|90px|Mitochondrial Physiology Society|MiPsociety]] L-Carnitine: from discovery to cardiometabolic risk markers.  +
MiP area Exercise physiology;nutrition;life style  +
Respiration and regulation Amino acid  +
Was submitted in year 2018  +
Was submitted to event MiP2018/MitoEAGLE Jurmala LV +
Was written by Dambrova M + , Liepins E +
Categories Abstracts
Modification date
"Modification date" is a predefined property that corresponds to the date of the last modification of a subject and is provided by Semantic MediaWiki.
06:51:29, 27 August 2018  +
hide properties that link here 
  No properties link to this page.
Enter the name of the page to start browsing from.